Abstract
The airway surface liquid (ASL) coats the lining of the airways and allows for efficient cilial movement and therefore effective mucociliary transport. Cell surface channels regulate the hydration status of the ASL and the two critical channels in the process are the cystic fibrosis transmembrane conductance regulator (CFTR) and the amiloride-sensitive epithelial sodium channel (ENaC). In cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) there is loss of CFTR function or compromised CFTR function in chronic bronchitis, respectively. CFTR function is required for chloride and bicarbonate section, and in collaboration with ENaC, maintains the normal pH and hydration status for the ASL. Interestingly, CFTR also regulates the channel activity of ENaC and dysregulation of ENaC exacerbates the CF phenotype in CFTR-related diseases. It has also been argued that increased ENaC activity results in decreased ASL thickness and mucous stasis. Although small molecule inhibitors such as amiloride have been tested as therapeutics, the adverse side effects on the renal ENaC inhibition that results in Na+ and fluid secretion have raised concerns about their safety. Here we discuss an alternative strategy proposed by Tarran and colleagues that employs a naturally occurring peptide inhibitor of ENaC, SPLUNC1, and how this peptide could be used as a potential therapeutic.

This publication has 47 references indexed in Scilit: